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Alopecia areata is a tissue restricted autoimmune
condition affecting the hair follicle, resulting in hair
loss. The goal of this study was to test the hypothesis
that the autoantigen of alopecia areata is melanocyte
associated. Potential autoantigens were tested in the
human scalp explant/Prkdscid CB-17 mouse transfer
system. Scalp T cells from lesional (bald) alopecia
areata scalp were cultured with antigen-presenting
cells, and antigen, along with interleukin-2. The
T cells were then injected into autologous lesional
scalp grafts on SCID mice, and hair regrowth was
measured. Hair follicle homogenate was used as an
autoantigen control. T cells cultured with melanoma
homogenate induced statistically signi®cant reduc-
tion in hair growth (p < 0.01 by ANOVA). HLA-A2-
restricted melanocyte peptide epitopes were then
tested with lesional scalp T cells from HLA-A2-posi-
tive alopecia areata patients. Melanocyte-peptide-
activated T cells signi®cantly reduced the number of
hairs regrowing in two experiments with six patients
(p < 0.001 by ANOVA). Injected scalp grafts showed
histologic and immunochemical changes of alopecia
areata. The most consistent peptide autoantigens
were the Gp100-derived G9-209 and G9-280
peptides, as well as MART-1 (27±35). Melanocyte
peptide epitopes can function as autoantigens for
alopecia areata. Multiple peptides were recognized,
suggesting epitope spreading. Key words: autoimmu-
nity/human/peptides/skin. J Invest Dermatol 117:1357±
1362, 2001
A
lopecia areata is a tissue restricted autoimmune
condition directed at the hair follicle, resulting in hair
loss. Patients frequently suffer severe psychiatric
consequences (Colon et al, 1991; Koo et al, 1994).
This is especially true of girls and young women who
become bald. The incidence of alopecia areata in the U.S.A.
(Minnesota) is 20.2 per 100,000 person-years, with a lifetime risk of
approximately 1.7% (Safavi et al, 1995). There is no signi®cant
gender difference. The disease is often chronic with a remitting,
relapsing course. Although it responds to immunosuppression,
generalized immunosuppression has signi®cant morbidity and
treatment is frequently frustrating and not successful. New
treatment options are essential. With evidence that alopecia areata
is a T-lymphocyte-mediated autoimmune condition, it has become
a model system for the study of pathogenesis and treatment of
T-cell-mediated autoimmunity, and as such is a model for a host
of additional T-cell-mediated autoimmune conditions.
Hair loss in alopecia areata is associated with a perifollicular
lymphocytic in®ltrate made up primarily of CD4+ cells, with a
CD8+ intrafollicular in®ltrate (Todes-Taylor et al, 1984), along
with expression of both HLA-DR and intercellular adhesion
molecule 1 (ICAM-1) on the follicular epithelium (Messenger and
Bleehen, 1985; Khoury et al, 1988). It is presumed that the
follicular expression of DR and ICAM-1 is induced by interferon-g
(INF-g). Lesional scalp from alopecia areata patients grafted onto
nude mice regrows hair coincident with a loss of in®ltrating
lymphocytes from the graft (Gilhar and Krueger, 1987). Alopecia
areata responds to immunosuppressive doses of systemic steroids.
The condition also has an association with additional autoimmune
processes such as autoimmune thyroiditis (Milgraum et al, 1987)
and vitiligo (Shellow et al, 1992). Circulating autoantibodies to
follicular structures are present in alopecia areata, but they are also
reported in normal controls (Tobin et al, 1997), and there is no
consistent pattern of reactivity of these antibodies. Furthermore, it
is not possible to transfer alopecia areata by injection of IgG into
human skin explants on nude mice (Gilhar et al, 1992).
Severe combined immunode®ciency (SCID) mice do not reject
human lymphocytes or skin. SCID mice grafted with human skin
and injected with human lymphocytes can be used to study the
immunopathogenesis of human skin conditions, and have been
used to demonstrate the role of lymphocytes in induction
(Boehncke et al, 1996; Wrone-Smith and Nickoloff, 1996) and
maintenance (Gilhar et al, 1997) of psoriasis lesions. We have since
extended this model to the use of human scalp explants on SCID
mice to study alopecia areata.
We have shown that it is possible to transfer alopecia areata to
human scalp explants on SCID mice by the injection of scalp-
in®ltrating T lymphocytes (Gilhar et al, 1998). It was necessary to
®rst activate the T lymphocytes in vitro by culture with hair follicle
homogenate in the presence of antigen-presenting cells (APC).
Culture with nonfollicular scalp homogenate did not induce hair
loss (Gilhar et al, 1999). Thus, alopecia areata is mediated by
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T lymphocytes that recognize a hair follicle antigen. We have since
found that optimal transfer of hair loss requires both CD4+ and
CD8+ T cells (Gilhar et al, in press). Depletion of either CD8+ T
cells (McElwee et al, 1996) or CD4+ T cells (McElwee et al, 1999)
can reverse alopecia areata in the Dundee experimental bald rat,
supporting a synergy or cooperation between CD8+ and CD4+ T
cells. In¯ammatory T cells of alopecia areata are cytotoxic and
possess both the Fas/Fas ligand and granzyme B cytotoxic
mechanisms (Bodemer et al, 2000). It is proposed that the CD4+
T cells provide help for the effector function of the CD8+ T cells.
It is hypothesized that the autoantigen of alopecia areata is
melanocyte derived (Paus et al, 1994). The initial basis for this is the
frequent clinical observation that with disease activity pigmented
hairs are lost preferentially to nonpigmented (e.g., white) hairs.
Furthermore, with regrowth, there is a tendency for the initial
regrowing hairs to be white. Melanocytes are a signi®cant
component of the hair bulb, which is the site of immunologic
attack. Furthermore, there is an association of alopecia areata with
vitiligo (Shong and Kim, 1991; Shellow et al, 1992), and hair bulb
melanocytes in alopecia areata show both histologic and ultra-
structural abnormalities (Tobin et al, 1990). It is possible to induce
lymphocyte-mediated alopecia in mice immunized against mela-
nocyte-associated (e.g., melanoma) antigens (Becker et al, 1996).
There is a large literature on melanocyte-associated T cell
epitopes generated by the search for melanoma-associated antigens
(Bakker et al, 1995; Rivoltini et al, 1995; Parkhurst et al, 1996;
Salgaller et al, 1996; Fleischhauer et al, 1997; Salazar-Onfray et al,
1997; Bettinotti et al, 1998; Kittlesen et al, 1998). Most interest has
focused on peptides presented by HLA-A2, which is present in
approximately half the population1. HLA-A2 may also be associated
with alopecia areata (Hordinsky et al, 1984). Many of the antigenic
peptides are derived from melanosome-associated proteins such as
gp100, MART-1/Melan-A, melanocortin 1 receptor (MC1R), or
tyrosinase, and are present in both normal melanocytes and
melanomas. MAGE antigens tend to be preferentially expressed
on melanoma cells, and are less likely to function as autoantigens for
alopecia areata.
The goal of this study was to test the hypothesis that melanocyte-
associated antigens can function as autoantigens to induce hair loss
in alopecia areata. For this purpose, HLA-A2-positive patients with
alopecia areata were selected for studies of HLA-A2-restricted
melanocyte peptide epitopes. Scalp T cells were cultured with
autologous APC and either hair follicle homogenate (positive
control) or melanocyte T cell epitopes. The cells were then
transferred to autologous scalp explants on SCID mice, inducing
hair loss.
MATERIALS AND METHODS
Patients Ten patients with either alopecia totalis or severe alopecia
areata were studied. Specimens from four patients were used for
experiments with melanoma homogenate, and specimens from six
patients were used for experiments with melanocyte-associated peptides.
HLA-A2-positive alopecia areata patients were selected for the peptide
component of this study. The four donors used for the melanoma
homogenate experiment were not HLA typed. Severe alopecia areata
was de®ned as large areas of alopecia with small residual areas of hair.
These patients would be categorized as S4 (76%±99% hair loss) by the
alopecia areata investigational assessment guidelines (Olsen et al, 1999).
Duration, age, sex, and clinical characteristics of all donors are listed in
Table I. There were no other preselection criteria, and data on these 10
patients were previously unpublished. Informed consent was obtained
after the nature and possible consequences of the studies were explained.
Protocols were approved by the Institutional Review Board. None of
the patients had any therapy in the 60 d before obtaining the scalp
biopsy specimens. HLA-A2 expression was determined by
microlymphocytotoxicity assay (Immunology Allergy and AIDS Institute,
Tissue Typing Laboratory, B. Rappaport Faculty of Medicine, Technion
and Rambam Medical Center, Haifa).
Punch biopsies (2 mm) from involved scalp were obtained from each
patient. Four biopsies from each patient were used for the isolation of
cutaneous T cells. Two biopsies were snap-frozen in liquid nitrogen for
immunoperoxidase staining. One frozen biopsy was sectioned vertically,
and the other was sectioned horizontally. An additional biopsy from each
patient was submitted for routine histologic examination with hematox-
ylin and eosin and horizontally sectioned in its entirety. Punch biopsies
(2 mm) were grafted to SCID mice in sets of three biopsies per mouse,
one mouse per group per subject.
Animals CB-17 Prkdcscid (SCID) mice (Charles River, U.K.), 2±
3 mo of age, were used in this study. The mice were raised in the
pathogen-free animal facility of the B. Rappaport Faculty of Medicine,
Technion-Israel Institute of Technology. Animal care and research
protocols were in accordance with institutional guidelines.
Skin grafting Graft transplantation to SCID mice was performed as
previously described (Gilhar and Krueger, 1987; Gilhar et al, 1988,
1998). Each 2 mm graft was inserted through an incision in the skin into
the subcutaneous tissue over the lateral thoracic cage of each mouse, and
covered with a standard Band Aid dressing. The dressing was removed
on day 7.
Isolation of T lymphocytes from scalp punch biopsies Four
punch biopsies from each patient were used for T cell isolation. Tissue-
in®ltrating lymphocytes were isolated from scalp punch biopsies with the
use of collagenase (Sigma, St Louis, MO), as described previously (Gilhar
et al, 1998).
Isolation of human peripheral blood mononuclear cells
(PBMC) PBMC were isolated from heparinized whole blood by
centrifugation over Hypaque 1077 (Amersham Pharmacia Biotech,
Uppsala, Sweden).
Hair follicle homogenate preparation Anagen hair follicles were
isolated under a stereodissecting microscope from normal scalp biopsies
obtained from healthy subjects who underwent hair transplantation
procedures. The follicles were homogenized and processed as previously
described (Gilhar et al, 1998).
Peptides Peptides were selected based on identi®cation in the
literature as HLA-A2-restricted melanocyte (e.g., melanoma) associated T
cell epitopes. The following peptides were commercially synthesized
(Chiron Technologies, Raleigh, NC) with free amino and carboxylic
acid termini: Gp100/G9-154, KTWGQYWQV (Bakker et al, 1995;
Parkhurst et al, 1996; Salgaller et al, 1996); Gp100/G9-209,
ITDQVPFSV (Bakker et al, 1995; Parkhurst et al, 1996; Salgaller et al,
1996); Gp100/G9-280, YLEPGPVTA (Bakker et al, 1995; Parkhurst et
al, 1996; Salgaller et al, 1996); MC1R 291, AIIDPLIYA (Salazar-Onfray
et al, 1997); MC1R 244, TILLGIFFL (Salazar-Onfray et al, 1997);
MC1R 283, FLALIICNA (Salazar-Onfray et al, 1997); MART-1 (27±
35), AAGIGILTV (Bettinotti et al, 1998; Rivoltini et al, 1995); and
tyrosinase, AFLPWHRFL (Kang et al, 1995). Peptides were negative for
endotoxin by the Limulus Amebocyte Lysate method (Bactochem, Nes
Ziona, Israel).
Human melanoma cells MeWo cells were obtained from Dr. Z.
Smetana (Central Virology Laboratory, Chaim Sheba Medical Center,
Table I. Clinical summary of alopecia areata patients
Patient Age Sex Alopecia subtype Duration
A 31 F Severea 8 y
B 32 M Severe 4 y
C 26 F Severe 10 y
D 26 F Severe 10 y
1 23 M Severe 7 y
2 39 F Severe 2 y
3 36 M Severe 2 y
4 32 M Totalis 6 y
5 22 F Severe 10 y
6 31 M Totalis 10 y
aSevere alopecia areata is de®ned as large areas of alopecia with small residual
areas of hair, or nearly complete alopecia totalis (76%±99% hair loss). Donors A±D
were studied in the melanoma homogenate experiment. Donors 1±6 are HLA-A2
positive and were studied in the melanomo peptide experiments.
1Antigen frequencies from Histocompatibility Testing 1980. Los Angeles:
UCLA Tissue Typing Laboratory, 1980.
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Tel Hashomer, Israel) (Sauvaigo et al, 1986). They were propagated in
RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 1%
glutamine, 1% sodium pyruvate, plus penicillin/streptomycin.
Culture of T lymphocytes Lymphocytes were plated at 1 3 105
cells per well in RPMI-FCS, along with irradiated (5000 R) PBMC
(1 3 105 cells per well) in 24 plate wells (Greiner, Lake Mary, FL), as
feeders. After 3 d of culture, recombinant interleukin-2 (rIL-2, 10 U per
ml; Genzyme Diagnostics, San Carlos, CA) was added. Every 7 d the T
cells were re-stimulated with feeders, for a total of 21 d culture. As
indicated for experimental groups, lymphocytes were stimulated with
either follicular homogenate (10 mg per ml) or peptide (10 mg per ml),
along with the feeder cells at each stimulation.
Phenotypic characterization of cultured T
lymphocytes Phenotype of the cultured T cell lines was determined
by immunocytochemistry on cytospin preparations, using procedures we
have previously published (Gilhar et al, 1997). This approach was
preferred over cyto¯uorograph analysis because of the small numbers of
cells available. The following monoclonal antibodies were used: anti-
CD3 FITC (clone SK 7, Becton Dickinson), anti-CD4 (IgG2a, S3.5),
anti-CD8 (IgG2a, 3B5) (Caltag, Burlingame, CA), anti-HLA-DR
(IgG2a, DK22, Dako, Glostrup, Denmark). Subtype matched mouse
IgG-FITC (Becton Dickinson) was used as a negative control.
Injection of cultured T lymphocytes into grafts on SCID
mice The SCID mice bearing grafts of lesional scalp were divided into
groups as indicated for each experiment. Between the twenty-third and
thirtieth days, the grafts were injected intradermally (0.1 ml) with
autologous lymphocytes as noted for each experiment. On day 90
biopsies were obtained for immunohistochemical and histologic analysis.
Both the percentage of grafts with hair and the number of hairs per graft
were recorded.
Immunohistochemical staining Staining was performed as reported
previously (Gilhar et al, 1998). Monoclonal antibodies to human antigens
used were as follows: anti-HLA-DR, anti-CD54 (ICAM-1) (Biodesign,
Carmel, NY), anti-CD3, anti-CD4, anti-CD8, anti-CD25 (Dako), and
anti-HLA-class 1 (Dako). Each specimen was coded at the time of
biopsy and evaluated by two observers who were blind to the coding.
Statistical analysis Statistical analysis was carried out using ANOVA
for multiple comparisons.
RESULTS
Melanocyte-associated antigens can function as
autoantigens in alopecia areata Lesional scalp T cells were
cultured with human melanoma cell homogenates (MeWo cells) in
two concentrations (10 mg per ml and 30 mg per ml), along with
autologous APC and IL-2 for 24 d. The positive control was
provided by incubation of scalp T cells with hair follicle
homogenate as a source of autoantigen. Scalp T lymphocytes
recovered from the cultures with melanoma homogenate (30 mg
per ml) were then injected into autologous scalp grafts on SCID
mice, as were scalp T cells incubated with hair follicle homogenate,
or APC alone with IL-2. Signi®cant (p < 0.01 by ANOVA) hair
loss was noted in grafts injected with T cells incubated either with
human melanoma homogenate (MeWo cells) or human hair follicle
homogenate. Figure 1 shows results from four patients. This
demonstrates that it was possible to transfer alopecia areata to scalp
explants on SCID mice by activation of lesional T cells with
melanoma antigens.
HLA-2-restricted melanoma peptide epitopes can act as
autoantigens for transfer of hair loss in the human scalp
explant/SCID mouse system HLA-A2-restricted
melanocyte peptide epitopes were tested as potential autoantigens
for alopecia areata. HLA-A2-positive alopecia areata patients were
selected for this study. In a preliminary study, PBMC from these
patients were incubated with a panel of melanoma peptides at
10 mg per ml, and then cultured with IL-2. Fresh APC and peptide
were added to the cultures every 7 d. At the end of 24 d of culture
the viable cell recovery was determined by trypan blue count. The
results from this preliminary experiment were used to determine
the choice of peptide for each donor in the subsequent experiment
using lesional scalp T cells. It would be expected that the
autoreactive T cells would be enriched in lesional skin relative to
peripheral blood (Kalish and Johnson, 1990).
For transfer experiments, lesional scalp lymphocytes from six
HLA-A2-positive donors were cultured with autologous APC, plus
either IL-2 medium alone, hair follicle homogenate (positive
control), or one or two melanocyte T cell epitope peptides.
Table II shows the lymphocyte recovery after 24 d. The initial
number of lymphocytes per group was 5 3 105. Cell recovery
from peptide and follicular homogenate groups varied between
5.8 3 106 and 19 3 106. The responding T cells were phenotyped
by immunohistochemistry analysis of cytospin preparations
(Table III). The T cells were shown to be activated as judged
by expression of CD25 (19%±30% positive). CD4+ T cells
predominated for all donors.
Lesional scalp T cells from the above cultures (Table II) were
injected into autologous scalp grafts on SCID mice as previously
described. Six donors, all HLA-A2 positive, were used in two
experiments. The negative control scalp grafts were not injected
with T cells. Additional negative control scalp grafts were injected
with T cells cultured with APC and IL-2 in the absence of
exogenous antigen, or PBMC activated with IL-2 alone. Positive
control grafts were injected with T cells cultured with follicular
homogenate. Melanoma peptide was added, along with APC, to
the T cells cultured in the ®nal group as indicated in Table II.
Melanoma-peptide-activated T cells were able to signi®cantly (p
< 0.001 by ANOVA) reduce the numbers of hairs regrowing in
both experiments (Table IV). T cells incubated with follicular
homogenate also resulted in signi®cant reduction in hair numbers.
There was no reduction of hairs in grafts injected with T cells
cultured with IL-2 and APC, or PBMC. For all six donors, no hairs
were present at day 90 in any of the three grafts per donor from
grafts injected with T cells activated by either melanocyte peptides,
or hair follicle homogenate. This demonstrates that melanocyte
peptide epitopes are capable of activating T cells to induce hair loss
in alopecia areata.
Melanocyte-peptide-induced transfer of alopecia areata
induces the histologic and immunologic features of
alopecia areata Biopsies were taken from the mice in the
above experiment after 90 d and were analyzed by both histology
and immunohistochemistry. Noninjected grafts showed growth of
normal terminal anagen hairs. Injected grafts, by contrast, showed
dystrophic hair follicles with a dense in®ltrate of CD4+ T cells, as
well as an intrafollicular in®ltrate of CD8+ T cells (Fig 2). In
contrast to noninjected grafts, the follicular epithelium of the
injected grafts expressed HLA-A, HLA-B, HLA-C, HLA-DR, and
ICAM-1 (Fig 2). These are known features of active alopecia
areata.
Figure 1. Hair loss induced by melanoma antigen. Signi®cant
(p < 0.01 by ANOVA) hair loss was noted in grafts injected with T cells
incubated either with human melanoma homogenate (MeWo cells)
30 mg per ml or human hair follicle homogenate. Data represent four
donors.
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DISCUSSION
The goal of this study was to test the hypothesis that melanocyte-
associated antigens can function as autoantigens in alopecia areata.
This was tested by isolating T cells from lesional scalp of alopecia
areata patients and culturing them with autologous APC, IL-2, and
potential autoantigens. The T cells were then injected into
autologous scalp explants on SCID mice. Hair regrows on these
scalp explants unless they are injected with autologous T cells that
have been appropriately activated. Previously we have demon-
strated that homogenized hair follicle provides an autoantigen that
can activate T cells for the transfer of alopecia areata. It was found
that melanoma homogenate and melanocyte T cell epitopes can
likewise activate scalp T cells to prevent hair growth and induce
hair loss.
The melanocyte-associated T cell epitopes used for this study
were originally identi®ed as HLA-A2-restricted melanoma-associ-
ated T cell epitopes recognized by CD8+ T cells. We have
previously demonstrated that transfer of alopecia areata requires an
interaction between CD8+ and CD4+ T cells, which was the
reason for our choice of these peptides. HLA-A2 may be weakly
associated with alopecia areata (Hordinsky et al, 1984). In our
screening, many alopecia areata patients were HLA-A2 negative,
however. It is likely that other melanocyte-associated T cell
epitopes, restricted by additional HLA alleles, can function as
autoantigens in alopecia areata.
Five HLA-A2-restricted melanocyte peptides were identi®ed
with the ability to act as autoantigens in alopecia areata (Gp100/
G9-154, Gp100/G9-280, Gp100/G9-209, MC1R 291, MART-1
27±35). The initial choice of peptides tested was biased by those
previously reported in the melanoma literature. It is likely that the
most immunodominant epitopes were preferentially identi®ed,
however. Obviously, there is no single melanocyte antigen, or
epitope, which is generally associated with alopecia areata. Epitope
spreading is likely to have a role in the broad nature of the
antimelanocyte response.
The observation that alopecia areata can be transferred by scalp T
cells activated by hair follicle homogenate has proven to be highly
reproducible. The effect has been observed to date in a total of 27
patients. This includes the initial published series of six patients
(Gilhar et al, 1998), 11 patients studied in CD4/CD8 separation
experiments (Gilhar et al, in press), as well as a positive control for
the 10 patients in this report. Aside from the six patients in this
study selected for HLA-A2 positivity, the patients were not
Table III. Phenotype of scalp T cells from HLA-A2+ donors responding to peptide epitopesa
Antigen P-1 P-2 P-3 P-4 P-6
Peptide Gp100/G9-280 MC1R 291 Gp100/G9-280 MART-1 27±35 Gp100\G9-154
CD4+ 54% 85% 39% 54% 55%
CD8+ 36% 15% 26% 40% 36%
CD25+ 25% 21% 19% 30% 25%
aPhenotype was determined by immunohistochemistry on cytospin preparations.
Table IV. Effects of melanocyte peptide stimulation on hairs per grafta
Group Antigen stimulus
Experiment 1
Donors 1, 2, 3
Hairs per graft (STD)
Experiment 2
Donors 4, 5, 6
Hairs per graft (STD)
1 No T cells injected 3.8 6 0.5 3.5 6 1.7
2 Hair follicle homogenate 0.0 6 0 0.0 6 0
3 Autologous PBMC 3.2 6 0.5 3.4 6 1.6
4 Scalp T cells in IL-2, no homogenate 3.5 6 0.5 ND
5 Peptide A 0.0 6 0 0.0 6 0
6 Peptide B ND 0.0 6 0
aScalp T cells or PBMC were incubated with either irradiated autologous PBMC and IL-2 alone or antigen provided by either hair follicle homogenate or melanocytic
peptides for 24 d. The T cells were then injected into autologous scalp explants on SCID mice, and hair growth was observed. The above data were obtained at 90 d. The
patients and peptides studied above correspond to numbers in Tables I±III. The following comparisons are all signi®cant for both experiments (p < 0.001 by ANOVA),
peptide A versus PBMC, peptide B versus PBMC, hair follicle homogenate versus PBMC, hair follicle homogenate versus no T cells.
Table II. Recovery of scalp T cells after culture with melanocyte peptide epitopes, and hair follicle homogenate HLA-A2
alopecia areata patients
Antigen P-1 P-2 P-3 P-4 P-5 P-6
APC + IL-2, no antigen 3.9a 5.2 3.5 4.5 11.0 3.0
Follicle homogenate 6.9 8.1 5.8 6.9 14.0 6.9
Peptide A 10.0 11.0 6.9 9.4 12.0 7.0
Peptide A Gp100/G9-280 MC1R 291 Gp100/G9-280 Gp100/G9-280 Gp100/G9-280 Gp100\G9-154
Peptide B NA NA NA 6.7 19.0 6.5
Peptide B NA NA NA MART-1 27±35 MART-1 27±35 Gp100/G9-209
aCell recovery3106 after 24 d culture with APC, and antigens as shown. Data are shown for a total of six patients. Initial cell number was 5 3104 for all groups. All pa-
tients were HLA-A2 positive. Donors 1±6 correspond to the donor numbers in Table I.
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screened, or selected for any criteria other than the clinical ®ndings
listed.
The ability of T cells to transfer alopecia areata is not a
nonspeci®c effect of activated T cells, but is speci®c for T cells
activated by culture with hair follicle homogenate or melanocyte-
associated antigens. Both scalp and peripheral blood T cells
activated by IL-2 alone were unable to transfer hair loss, as were
peripheral blood T cells activated with phytohemagglutinin (Gilhar
et al, 1998). Furthermore, scalp T cells incubated with nonfollicular
scalp homogenate were not effective (Gilhar et al, 1999). The
requirement for scalp T cells is believed to re¯ect a greater
precursor frequency in lesional skin than peripheral blood. Thus,
transfer of hair loss is not a nonspeci®c effect of injection of
activated T cells, but appears to require activation of T cells by the
relevant autoantigen.
It was necessary to use lesional (bald) scalp for the explants
because transplantation of noninvolved scalp or scalp from normal
donors results in loss of hair with inadequate regrowth (Gilhar et al,
1988). Hair loss following grafting occurs with grafting of human
scalp to both humans (e.g., hair transplants) and mice. In our
experience with grafts of human scalp to immunode®cient mice,
the number of hairs regrowing from a 2 mm graft is insuf®cient for
analysis, whereas there is suf®cient hair regrowth from grafts of
involved (bald) alopecia scalp (Gilhar and Krueger, 1987). For this
reason, it was not possible to perform these experiments with
noninvolved or normal scalp explants. The difference in hair
regrowth following grafting of normal terminal hair follicles versus
miniaturized follicles of alopecia areata may be a function of
vascular requirements of the large terminal hair follicles. As
involved scalp was studied, this model represents relapse of alopecia
areata rather than initial induction of disease. This is an appropriate
model for this condition, which is marked by multiple relapses.
One of the features of alopecia areata is aberrant expression of
HLA-A, HLA-B, HLA-C on the follicular epithelium of the hair
bulb (Brocker et al, 1987). Normal hair bulb epithelium is unusual
in that it lacks expression of HLA-A, HLA-B, HLA-C and may
represent an immune privileged site. Paus et al (1994) have
hypothesized that induction of class I MHC in alopecia areata
allows an autoaggressive response by melanocyte-reactive CD8+ T
cells. The authors suggested that the CD8+ cells induce HLA-DR
on the affected hair follicles by production of IFN-g, resulting in a
second wave of CD4+ cells. We have previously reported the
presence of CD4+ autoreactive T cells in the in®ltrate of alopecia
areata (Kalish et al, 1992), as well as a need for both CD4+ and
CD8+ T cells to transfer alopecia areata (Gilhar et al, in press). This
report supports the hypothesis of Paus on the role of melanocyte
autoantigens in alopecia areata. Future work will concentrate on
identifying the range of melanocyte-associated autoantigens in
multiple HLA backgrounds, as well as translating this knowledge to
therapeutic bene®t.
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